Business Wire

Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the results of global phase II study of anti-IL-31 receptor A, humanized monoclonal antibody, nemolizumab (CIM331), which is currently developed for atopic dermatitis, were released at the annual meeting of the American Academy of Dermatology currently held in Washington, D.C.
The results were released at the Late-breaking Research Forums at 10:00 on Saturday, March 5 (local time).

The global phase II study was conducted to evaluate the efficacy and safety of CIM331 in 264 patients with moderate to severe atopic dermatitis. Efficacy and tolerability for 12 weeks treatment were observed in this study.

“Itch in atopic dermatitis disturbs sleep and quality of life of those who suffer from the disease. Moreover, the itch-scratch cycle may aggravate symptoms of dermatitis. CIM331 is a drug candidate with a novel mechanism of action, which improves dermatitis by blocking the itch-scratch cycle,” said Chugai’s Director and Executive Vice President, Dr. Yutaka Tanaka. “We are delighted that the efficacy and safety results in this study have demonstrated the possibility of CIM331 to provide a new treatment concept for patients around the world.”

[Study overview]
Patients were randomized to one of the following four CIM331 dose groups or placebo group in the ratio of 1:1:1:1:1.

  • CIM331 (0.1 mg/kg) subcutaneous dosing every 4 weeks (Day 1, Week 4, and Week 8)
  • CIM331 (0.5 mg/kg) subcutaneous dosing every 4 weeks (Day 1, Week 4, and Week 8)
  • CIM331 (2.0 mg/kg) subcutaneous dosing every 4 weeks (Day 1, Week 4, and Week 8)
  • CIM331 (2.0 mg/kg) subcutaneous dosing every 8 weeks (reference group)
  • Placebo subcutaneous dosing every 4 weeks (Day 1, Week 4, and Week 8)

[Study results]
Efficacy

  • The percent change in pruritus VAS at Week 12, which was the primary endpoint, was significantly higher in the CIM331 treatment groups than in the placebo group (p<0.01 in all).
 
   

Placebo
every 4 weeks

  0.1 mg/kg
every 4 weeks
  0.5 mg/kg
every 4 weeks
  2.0 mg/kg
every 4 weeks

Percent change in
pruritus VAS
(At Week 12; %)

  -20.1   -41.5   -61.2   -60.5
  • In addition, dermatitis endpoints (i.e. EASI and sIGA) and sleep quality endpoints (i.e. sleep onset latency and total sleep time) were presented.

Safety

  • Tolerability was observed in CIM331 treatment groups. Adverse events reported relatively frequently were atopic dermatitis and nasopharyngitis.

About Late-breaking Research Forums
This session will highlight the latest ground-breaking clinical and basic research performed. New therapies will be given top priority, particularly data from pivotal trails of unapproved drugs or unapproved indications. In addition, novel observations that could be practice changing will also be given top consideration.

About nemolizumab (CIM331)
It is a humanized anti-human-IL-31-receptor-A (IL-31RA) monoclonal antibody. IL-31 is identified as a cytokine that can induce the pruritus, and reported to be associated with pruritus in atopic dermatitis and dialysis patients. Nemolizumab works by inhibiting biological activity of IL-31 through competitively blocking the binding of IL-31 to its receptor.

About pruritus VAS
Pruritus VAS stands for pruritus visual analogue scale, by which the severity of pruritus is measured with a 10 cm scale on which patients draw a line to express their assessment of severity (0: no itch, 10: worst imaginable itch).

About EASI
EASI (Eczema Area and Severity Index) is a tool to demonstrate severity of dermatitis with score from 0 to 72.

About sIGA
sIGA (static Investigator’s Global Assessment) is a tool to evaluate overall severity of dermatitis with a six-level scale from 0 to 5 (0: clear, 5: very severe).

About Itch-scratch cycle
Skin itchiness causes scratch, which enhances inflammation and further aggregation of itchiness. This vicious cycle called the itch-scratch cycle is known as an exacerbating factor for dermatitis.

About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals, and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2015 of Chugai totalled 498.8 billion yen and the operating income was 90.7 billion yen (IFRS Core basis).
Additional information is available on the internet at http://www.chugai-pharm.co.jp/english.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA, Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

FlipNpik Opens Its Private Sale to Public and Introduces Fiat-Based Payment Gateway19.7.2018 08:00Pressemelding

In an unprecedented move, FlipNpik, the blockchain-powered social media platform for local businesses, democratises its private sale and allows everyone to enjoy the privileges and bonuses traditionally reserved only for the large investors. Known as 'whales', these powerful investors typically enjoy large bonuses during the private sale phase of ICOs (Initial Coin Offerings). FlipNpik now turns this practice on its head by eliminating the large investment required to benefit from the 'whale' bonus, which offers up to 100% bonus of FNP (FlipNpik) tokens to the public, leveling the playing field for small investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005283/en/ Monetize your social media posts by supporting local shops (Graphic: Business Wire) Deploying one of the first fiat-based payment gateways using money transfers to facilitate ICO payments, FlipNpik also allows the larger community who may be new to bu

Pat Johnson Joins UniPrint Team in Europe19.7.2018 07:35Pressemelding

UniPrint.net announced today that Pat Johnson has joined the company to support and develop their EMEA Partner Program, as well as with the promotion of their highly successful Cloud solutions UniPrint Infinity™ and ePRINTit™. Pat brings with him 20 years of experience at Xerox UK where he was instrumental in engaging with software vendors to support Xerox Connectkey products and Xerox Business Partner Channels. In joining UniPrint.net, Pat is well placed to support the continued growth of UniPrint.net EMEA Partners with the UniPrint product portfolio. Pat will hold the new position of MPS Partner & Strategy Manager EMEA, continuing UniPrint’s success in engaging valued business partners towards a modern approach for Software as a Service (SaaS) and Cloud printing solutions. Pat comments: “I am excited to start a new challenge within UniPrint.net and I look forward to working with the EMEA team to further develop their Partner Program. I am fortunate to be joining a respected company w

The Poseidon Foundation: Liverpool Bids to Be First ‘Climate Positive’ City by End of 202019.7.2018 07:34Pressemelding

The Poseidon Foundation (“Poseidon”) have signed a ground-breaking partnership with Liverpool City Council in a bid to make Liverpool the world’s first climate positive city by the end of 2020. The city council has signed an agreement with Poseidon to integrate its ground-breaking blockchain-powered platform into Liverpool’s day to day operations. Poseidon’s technology offsets the carbon impact of any product or service by transparently supporting essential forest conservation projects, allowing individuals, organisations and governments to reverse the impact of climate change every day through their activities. Poseidon will be moving its operations to the city in order to play a key role in Liverpool’s new climate positive strategy, which will be trialled over the next 12 months. Poseidon, who are already working closely with Liverpool company BAC Mono to create the world’ first climate positive car, will work with local schools, universities and businesses to develop educational pro

Elliott Advisors (UK) Statement on thyssenkrupp AG19.7.2018 07:30Pressemelding

Funds advised by Elliott Advisors (UK) Limited (“Elliott”) are significant shareholders in thyssenkrupp AG (“thyssenkrupp” or the “Company”). Elliott notes recent press coverage referencing the contents of a private letter Elliott sent to the thyssenkrupp Supervisory Board yesterday morning. In order to avoid any misunderstandings or misrepresentations of its substance, Elliott is hereby making the full text of the letter public. *** The Members of the Supervisory Board thyssenkrupp AG thyssenkrupp Allee 1 45143 Essen 18 July 2018 Ladies and Gentlemen, We note the resignation of Professor Dr. Ulrich Lehner as chairman of the Supervisory Board of thyssenkrupp AG. When we met with Professor Lehner in Essen on 27th June he and we assured each other of our desire to develop a constructive working relationship. Professor Lehner’s comments in the interview he gave to Die Zeit on 12th July suggest that he did not give those assurances in good faith. In the course of the interview with Die Zei

Albar Capital Deploys FlexNOW19.7.2018 07:30Pressemelding

FlexTrade (@FlexTrade) today announced that Albar Capital Ltd., a new hedge fund led by Javier Velazquez (formerly of Millennium Capital Partners LLP), is now trading equities and futures using FlexNOW, FlexTrade’s new execution management system. “The FlexNOW team was instrumental in solving several of our problems,” said Jason Ruder, Trader at Albar Capital. “Not only are they helping us with our compliance requirements, they are also responsive to requests that improve my workflow.” According to Rhyd Lewis, FlexNOW Product Manager, FlexNOW’s quick onboarding and easy installation process was critical for Albar Capital’s launch on 2 July. “We had no problem integrating FlexNOW with Albar’s portfolio and risk management platform, Paladyne, which allows Fund Managers to route orders to the dealing desk,” said Lewis. “Additionally, Albar has connectivity to their executing venues via FlexTrade’s zero-touch broker network.” Multi-Asset, MiFID II Compliant Trading Designed to handle tradi

Entersekt Signs on to Mobile Connect19.7.2018 07:00Pressemelding

Entersekt, an innovator in mobile-first fintech solutions, today announced it has signed an agreement with the GSMA to offer Mobile Connect to its institutional customers. Developed by the mobile industry as a universal mobile-device–based authentication service, Mobile Connect allows consumers across the globe to access their digital accounts via a single login. Users of the service do not have to remember multiple usernames and passwords. Instead, they identify themselves with their unique mobile number, together with a second factor like a PIN or biometric scan when additional security is required. Entersekt already offers advanced authentication and app security solutions, but the company believes Mobile Connect could help it address several increasingly urgent challenges banks face in streamlining customer-facing digital interactions. The service can facilitate the sharing with digital service providers of mobile-operator–held user and device data – and it is contextual informatio